stockrowVertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024.
- Revenue
- +11.9%
- EPS
- −39.2%
- Free cash flow
- −52.1%
Quarter to September 2026, against a year earlier
Follow VRTX
Alert me
Vertex Pharmaceuticals Incorporated (VRTX) EPS (diluted)
Vertex Pharmaceuticals Incorporated's EPS (diluted) for fiscal 2025 was $15.32, compared with −$2.08 in fiscal 2024. Over the twelve months to 30 September 2026 it was $15.54. Over the past ten years it has ranged from −$2.31 (fiscal 2015) to $15.32 (fiscal 2025) — the current reading is the highest in ten years. Vertex Pharmaceuticals Incorporated ranks 9th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $15.32 | — |
| FY2024 | −$2.08 | — |
| FY2023 | $13.89 | 8.35% |
| FY2022 | $12.82 | 42.29% |
| FY2021 | $9.01 | (12.44%) |
| FY2020 | $10.29 | 128.16% |
| FY2019 | $4.51 | (44.25%) |
| FY2018 | $8.09 | 677.88% |
| FY2017 | $1.04 | — |
| FY2016 | −$0.46 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $2.56 | (40.58%) |
| Jun 2026 | $4.31 | 7.21% |
| Mar 2026 | $4.02 | (13.55%) |
| Dec 2025 | $4.65 | 10.71% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | $45.29 |
| ARGX argenex SE compare | $28.66 |
| VRTX Vertex Pharmaceuticals Incorporated | $15.54 |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $5.68 |
| RPRX Royalty Pharma PLC compare | $1.40 |
| GMAB Genmab A/S Sponsored ADR compare | $1.27 |
| ROIV Roivant Sciences Ltd. compare | −$0.53 |
| MRNA Moderna, Inc. compare | −$7.99 |
| RVMD Revolution Medicines, Inc. compare | −$9.11 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on VRTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement